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Background: Currently there are 19 million people in Africa with diabetes, mainly Type 2 diabetes 
(T2DM) (95%), estimated to grow to 47 million people by 2045. However, there are concerns with 
early diagnosis of patients with Type 1 diabetes (T1DM) with often patients presenting late with 
complications. Concerns also to access and affordability of insulin and affordability of monitoring 
equipment and test strips with typically high patient co-payments with potentially catastrophic 
consequences for families. This negatively impacts on the quality of care adversely affecting morbidity 
and mortality. There are also issues of patient education and psychosocial support affecting patients’ 
quality of life. These challenges need to be debated and potential future activities discussed to 
improve the future care of patients with T1DM across Africa. Methodology: Documentation of the 
current situation across Africa including the epidemiology and economics of diabetes as well as 
facilities and available treatments within public healthcare system for patients with T1DM. In addition, 
ongoing activities to improve future care. Subsequently, contextualise the findings with input from 
senior level government, academic and other professionals from across Africa to provide future 
guidance. Results: Whilst the prevalence rates for T1DM are considerably lower than T2DM, there are 
ongoing concerns with late diagnosis of T1DM as well as the routine provision of insulin and 
monitoring equipment across Africa. High patient co-payments exacerbate the situation. There are 
ongoing developments to address this including the instigation of universal health care and 
partnerships with non-governmental organisations, patient organisations and pharmaceutical 
companies to improve future care. Their impact remains to be seen. A range of activities have been 
documented for all key stakeholder groups to improve future care. Conclusion: There are concerns 
with the management of patients with T1DM across Africa. A number of activities have been 
suggested to address this and will be monitored.
1. Introduction
The focus on the management of patients with diabetes in Africa has increased considerably in recent 
years driven by growing prevalence rates as well as increasing costs to healthcare systems (1-3). 
Alongside this, there is increasing morbidity and mortality from non-communicable diseases (NCDs) 
including diabetes as well as cardiovascular diseases and hypertension (4-7), as well as and 
increasing comorbidity with HIV and TB especially among children (8, 9), focusing key stakeholder 
attention on the care of patients with diabetes. In South Africa for instance as a result of rising 

































































prevalence rates, diabetes is currently the second most common cause among recorded deaths (10, 
11). Diabetes, including Type 1 diabetes (T1DM), is also known to adversely affect patients’ quality of 
life due to the diabetes related complications (12-18).
Current estimates suggest that approximately 19 million people in Africa have diabetes with an 
estimated 47 million likely to have diabetes by 2045 (19, 20), with almost a third of patients needing 
insulin for their diabetes (21). High prevalence rates are seen particularly among North African 
countries (22, 23). Other authors publishing in 2016 suggested that up to 29.3million people in Africa 
had diabetes (17). In 2015, approximately 321,000 deaths in sub-Saharan Africa (SSA) were 
attributable to diabetes, with most of these occurring in people 60 or under (1, 24). This increased to 
366,200 across Africa in 2019 (20). Concerns with insulin costs, insulin resistance, and the 
inaccessibility of insulins are key contributing factors to current mortality rates (21). 
High prevalence rates for diabetes have resulted in estimates that approximately US$10·81 billion 
was spent on direct medical costs in 2015 for treating patients with diabetes in SSA, with out-of-
pocket expenditure likely to exceed 50% of overall health expenditure in a number of African countries 
(1). Total costs increased to US$13billion across Africa in 2019 for patients aged between 20 to 79 
years (20).These costs are exacerbated by the fact that patients with diabetes in hospitals have the 
longest stay due to diverse complications including stroke and amputations (12, 25). The total costs 
for treating patients with diabetes in SSA including direct medical costs are likely to increase to 
US$59.32billion by 2030 (1), most of which will be for treating patients with type 2 diabetes (T2DM). 
Costs will be enhanced by the lack of health technologies to screen, diagnose and effectively manage 
patients with diabetes. Having said this, less than 10% of the total worldwide costs for treating 
patients with diabetes are currently from the African, North African, South East Asian and Middle East 
Regions combined (26). The cost of treating patients with T1DM in Africa is typically higher compared 
with T2DM patients at a ratio between 1.80 to 5.66 (27), with others calculating ratios of between 1.5 
to 4.4 although taking into account more continents (27, 28)
There have also been cost estimates for treating diabetes among individual Africa countries. In 2015, 
Quaye et al estimated the mean annual financial cost of managing one diabetic case at hospital 
clinics in Ghana was US $372.65, with medicines accounting for 71% of the total financial cost (29). In 
2015, Pei estimated the total cost of diabetes for 40 households in Ghana, including patients with both 

































































T1DM and T2DM, was approximately 15,000 Cedi/month of which 66.5% was direct costs (30). In 
view of the expenditures involved, 52.9% of the households surveyed in Ghana have experienced 
catastrophic health expenditure when family members are diagnosed with diabetes (30). In Mali, 
patients with diabetes typically spend an average of US$230 per year on their treatment without 
adding in the cost for managing any complications, with the cost borne by the State in Mali for the 
treatment of diabetes without complications currently estimated at US$20million per year (21, 31) (see 
Table 2 for further details). Suleiman et al. (2014) estimated the annual direct costs of treating 
patients with T1DM in Nigeria was NGN18 billion (US$112. 54million), with costs of NGN100,032.89 
(US$625.21) per patient (32). In their review, Mutyambizi et al. (2018) estimated the national direct 
costs of treating patients with diabetes in Nigeria (T1DM and T2DM) was between I$3.5 to I$4.5 
billion per annum, which compares with estimated national costs (direct and indirect) in Morocco of 
between I$5.9 to I$8.2 billion per annum (27). 
There are concerns that governments and health systems across Africa are struggling to cope with 
the demand and cost of services to treat patients with diabetes and its complications unnecessarily 
increasing morbidity and mortality (1, 33). This includes concerns that children in Africa are at high 
risk of being diagnosed with T1DM only after complications occur, or when they are critically ill, due to 
a lack of knowledge among parents, caregivers and school teachers (34). This is beginning to change 
with several initiatives now in place across Africa to improve the management of patients with 
diabetes. These include patient led strategies to strengthen healthcare systems, strategies to improve 
guideline adherence where there are concerns with sub-optimal management, assist patients with 
appropriate lifestyle changes including diet and exercise, provide free medicines and diagnostic 
equipment as well as instigate quality targets (35-54).  There are also projects involving pharmacists 
educating patients about the signs and symptoms and treatments to improve self-management for 
those with chronic NCDs (55). Further details regarding ongoing strategies across Africa to improve 
the care of patients with diabetes are summarised in the recent paper of Godman et al (56).
The vast majority of patients with diabetes in Africa have T2DM, with higher prevalence rates of 
patients with T2DM versus T1DM seen in Africa compared with other parts of the world (1, 56-60). In 
their study published in 2008, Majaliwa et al. reported that incidence rates for patients with T1DM in 
Africa ranged from 1.5/100000 in Tanzania to 20/100000 in Morocco, with 9.8% of patients in Ethiopia 

































































attending diabetes clinics having T1DM (61). Higher rates are seen in children in SSA where T1DM is 
one of the most common endocrine and metabolic conditions (62, 63). Reported prevalence rates for 
patients with T1DM across Africa were low in 2011, ranging from 4 per 100,000 in Mozambique up to 
12 per 100,000 in Zambia (58). More recent incidence and prevalence rates are seen in Table 1. 
Typically, published figures demonstrate an increasing prevalence of T1DM across Africa (45, 57, 58, 
64-67), although this is not universal (57).  Current incidence and prevalence figures may be 
underestimates if parents fail to understand the features of childhood diabetes and do not take their 
children for diagnosis and treatment at healthcare facilities (30, 59, 63, 68), with estimates that up to 
half or more of patients with T1DM are not diagnosed (34, 69). 
Prevalence rates for patients with T1DM in Africa are likely to be higher if the age of diagnosis is 
extended up to 26 years as opposed to 0 to 14 years (1), enhanced by the age at diagnosis of T1DM 
typically higher among the black population in Africa compared with the white population (70). In 
Rwanda, recent studies suggest prevalence rates are over three times higher when young adults up 
to 26 years are included in epidemiological studies versus those only including children up to 14 years 
of age (71, 72). Similarly in Ethiopia, there was a rapid increase in the incidence of T1DM in children 
in their mid-teens up to the age of thirty compared with those under 15 years of age (73). 
Insert Table 1
In 2015, the International Diabetes Federation (IDF) believed there were 7600 new cases each year 
of diabetes among children in Africa (17), with generally higher rates among North African countries 
(17). Typically in Africa, children with diabetes are insulin-dependent and most likely autoimmune 
(74), with auto-immune beta-cell destruction having an important role in the pathogenesis of T1DM 
among African patients (75). There are a number of HLA class II alleles associated with T1DM among 
the black population in Southern Africa, which is important for care delivery (76). It is estimated that 
T1DM accounts for over 90% of children with diabetes (17, 63). The latest estimates (2019) from the 
IDF suggest there are 25,800 children and adolescents (0 – 19 years) with T1DM in Africa, with 
10,300 newly diagnosed cases each year (77). However, still a significant number of patients remain 
undiagnosed (34, 69, 77). There are also ongoing debates regarding the role of malnutrition in the 
development of T1DM among African children, as well as malnutrition-related diabetes, enhancing the 
poor prognosis for T1DM patients in Africa especially those from resource-poor settings (59, 73). 
 
Despite its impact on the health of patients including early mortality, there are still concerns that 

































































patients with T1DM are not receiving evidence based care  in Africa at the expense of ongoing 
strategies to reduce morbidity and mortality associated with T2DM (45, 56). Studies published in 2005 
documented high mortality rates for children with T1DM (78, 79). For instance, in Mozambique the life 
expectancy of children under 15 years with T1DM was 3.5 years (1). Common causes of death in 
African children with diabetes include diabetic ketoacidosis (DKA), severe hypoglycaemia, infection 
and eventually microvascular complications (17, 69, 80). Overall, DKA is the most common cause of 
death in children and adolescents with T1DM, accounting for approximately half of all deaths in 
patients younger than 24 years with diabetes (59, 81, 82). Typically at diagnosis of T1DM in Africa, up 
to 80% or more of children and adolescents newly diagnosed with T1DM have DKA (17, 34, 69, 80, 
83-85). Independent risk factors associated with DKA in children include their age, parents’ 
knowledge of the signs and symptoms of DKA, health care professional (HCP) education, erratic 
supply and poor adherence rates to prescribed medicines as well as infections before DKA (80, 86-
88). High mortality rates due to DKA in developing countries including African countries are due to 
higher rates of infection, less developed medical service as well as delays in seeking care with over 
reliance on traditional medicines and healers (69, 80, 81, 89, 90). Severe hypoglycaemia is also 
common among children in SSA, and is associated with high mortality (17, 65, 91) as well as a 
substantial impact on both productivity and healthcare utilisation (92). There are also concerns that 
lack of correction dosing for hyperglycaemia, lack of carbohydrate counting and lack of access to 
rapid-acting insulin among children with T1DM results in poor glycaemic control, which negatively 
impacts on the quality of life of patients (93). Having said this, good management of nocturnal and 
daytime non-severe hypoglycemic events that minimize hypoglycemia while maintaining good 
glycemic control may positively impact upon the psychological wellbeing of people with diabetes, 
reducing healthcare costs and improving productivity (94). Women with T1DM in their reproductive 
age should also be identified as a high-risk group where access to specialized prepregnancy clinics 
should be made available so that their T1DM can be intensively managed throughout pregnancy via a 
multidisciplinary team. The use of multiple insulin injection regimens, including the use of insulin 
aspart during pregnancy, is both well tolerated and effective, and may offer some benefits with 
respect to postprandial glycemic control. This is also a key consideration for the future as care for 
patients with T1DM improves (95). 
There are also concerns with the extent of complications among patients with T1DM across Africa 

































































including retinopathy, nephropathy, neuropathy and hypertension as well as infections including 
malaria and tuberculosis (1, 17, 59, 69, 96-98). Improved diet, family support offering psychosocial 
support, as well as family support by assisting with correct and constant administration of medicines, 
including insulin, can help to reduce the complications of T1DM (65). Psychosocial support is 
important with T1DM adversely affecting the quality of life of patients resulting in the need for all key 
stakeholder groups to work together to improve the care and lives of patients with T1DM (13, 14, 99, 
100). This includes the need to develop coping strategies and address issues of stigma (99), which 
are especially crucial if coping strategies involve avoiding injections (99). There is also a need to 
address concerns with the availability of dialysis services across Africa given current concerns (101, 
102). 
While mortality and morbidity rates have improved among African countries in recent years in patients 
with T1DM, the gains seen in Africa are far less than those seen in developed countries where there 
have been substantially greater declines in morbidity and mortality in recent years (45). For instance 
in Gabon, Damiens et al. (2019) estimated mortality at 7% approximately four years after T1DM 
diagnosis (57). Others have documented higher rates suggesting that up to 50% of patients with 
T1DM in Africa die in the first five years after diagnosis (57). In addition, among some African 
countries, the life expectancy of a child with T1DM can be as low as one year (103). There are a 
number of elements of care that adversely affect improvements in the morbidity and mortality of 
African patients with T1DM (45). These include failure to seek help, unavailability of regular screening 
programmes, inability to make a formal diagnosis, inadequate and inappropriate care exacerbated by 
the lack of equipment, facilities and professionals, e.g. Ghana currently has less than fifteen 
endocrinologists, poor knowledge among patients and parents, frequent episodes of hypoglycaemia 
exacerbated by a lack of insulin and the cost of insulin as well as monitoring sticks and syringes, poor 
storage of insulin, poor adherence to treatments and poor eating habits as well as cultural aspects of 
care (1, 17, 21, 30, 45, 47, 48, 63, 65, 104-113). The WHO in 2015 found that in SSA only 51% of the 
countries had metformin routinely available and only 40% had insulin readily available, well below the 
80% target (1, 114). In addition, many African countries currently have inadequate facilities to manage 
both the microvascular and macrovascular complications of diabetes (1, 115). 
Overall in many African countries, patients with T1DM have been at a disadvantage with a greater 
focus on infectious diseases; however, as mentioned, this is starting to change (56, 80). We are also 

































































seeing programmes introduced among African countries to help transition patients from paediatric to 
adult services, and this is likely to grow as care is improved for children with T1DM in Africa (116). 
A key area to address to improve the management of patients with T1DM across Africa along with 
healthcare strengthening is access to, and regular availability, of insulins as well as increased 
availability of blood glucose monitoring devices (1, 50, 59, 69, 106). Previous studies have found that 
<25% of T1DM patients in the Democratic Republic of Congo had regular access to insulin <25% of 
the time and in Tanzania different types of insulin were available in public health facilities in only 8%–
17% of the time with one version of insulin was only available 34% of the time (59, 117). Poor 
availability and use of insulin are not helped by high costs and co-payments. Other key areas to 
address include patient empowerment on the knowledge about their disease and treatment to help 
reduce non-adherence to insulins and rates of hypoglycaemia (55, 118, 119). 
Table 2 provides more details regarding the economics and availability of insulin and glucose 
monitoring among African countries highlighting current challenges. Typically in Africa, the direct 
costs of treating diabetes approaches US$300/ patient corresponding to the annual income of many 
families (65). We are beginning to see access programmes and other approaches among African 
countries to address concerns with insulin availability as well as a lack of education and facilities, and 
these initiatives are likely to grow alongside moves to enhance universal healthcare across Africa (46, 
69, 120-123). This also includes addressing concerns with the availability of insulin analogues for 
insulin resistant cases exacerbated by cost considerations (107, 124, 125). We are also seeing 
groups such as the IDF improve access to HbA1c testing among African countries including 
Cameroon and Guinea (49, 50). For instance in the Cameroon, under the Changing Diabetes in 
Children (CdiC) programme, all children and adolescents attending relevant centres are provided with 
free insulin as well as glucose monitors and strips (48). Diabetes control has been reported to 
improve with the length of T1DM once patients had been through any denial phases and had 
accepted the condition and its implications on lifestyle requirements (48). Recently, the partnership 
between the Ministry of Health in Rwanda and Abbott through the Team Type 1 Foundation has 
resulted in the donation of glucose meters and nearly 12 million test strips to improve the diagnosis 
and management of patients with T1DM in Rwanda for the next four years (53), and this will be 
closely monitored to provide future guidance, 

































































The WHO lists soluble insulins and intermediate insulins in the 2019 Essential Medicines List (126), 
and these should be readily available to help patients with T1DM. However, there are concerns with 
the quality of low-cost generic insulins as these are more complex to produce than oral generic tablets 
(17, 106).
Insert Table 2
Consequently, the principal objective of this paper is to debate ongoing challenges and potential 
future activities that could be instigated to improve the care of patients with T1DM in Africa. This 
includes issues surrounding medicine availability and storage along with monitoring equipment and 
other measures to improve the care of patients with T1DM. There have been a number of systematic 
reviews and guidelines looking at key issues surrounding the management of patients with diabetes in 
Africa including the epidemiology, economics and initiatives to strengthen healthcare systems (1, 2, 
61, 62, 98, 109, 127-131). However to date, there have only been a limited number of publications 
that have comprehensively focused on all aspects of care covering epidemiology, diagnosis, 
education, and treatment including access to appropriate medicines and monitoring equipment as well 
as adherence rates. There have also only been a limited number of publications assessing the 
influence and impact of different interventions to improve the care of patients with T1DM across 
Africa. In view of this, we sought to document and discuss ongoing and potential activities that could 
be introduced for all key stakeholder groups across Africa to improve the future care of patients with 
T1DM. This includes contextualising the findings from a wide range of co-authors from across Africa 
and wider to provide future guidance. 
2. Methodology
We did not perform a systematic review for the reasons already given. However, there is an urgent 
need to improve the management of patients with T1DM in the public healthcare system across Africa 
building on recent publications. Consequently, we conducted a narrative review of the literature. In 
addition, in view of the paucity of publications researching the influence and impact of different 
interventions to improve the care of patients with T1DM, we used senior level personnel from 
governments and their advisers, clinicians, academia, rational medicine use advisers, HTA personnel, 
as well as patient organisation personnel, from across Africa and wider to suggest potential activities 
that could be introduced to improve the future care of patients with T1DM in Africa. This included both 
short- and long-term initiatives building on an understanding of the current situation in their country. 
The advice given to improve the care of patients with T1DM was based on the considerable 

































































knowledge and experience of the co-authors as well as publications known to them. The co-authors 
have come from a wide range of backgrounds and countries. We have successfully used this 
approach in previous publications to stimulate debate in other priority healthcare areas and situations 
to provide future guidance (56, 132-144).
We did not split the African countries into low- or middle-income countries as the issues surrounding 
the management of patients with T1DM appears to apply across Africa. Consequently, countries can 
learn from each other. We also did not review each paper to assess whether the presence of 
diabetes, especially T1DM, had been defined according to WHO and other internationally recognised 
diagnostic criteria in view of the objectives of this paper (130, 145).  
3. Findings and suggested activities
T1DM is typically diagnosed within primary healthcare centres (PHCs) in the public healthcare system 
among a number of African countries; alternatively, within district and tertiary hospitals. Generally, 
most patients with DKA are diagnosed at secondary and tertiary hospitals.
Table 3 contains details of treatments and facilities routinely available within the public healthcare 
systems among African countries to manage T1DM as well as its complications. As mentioned, the 
WHO Essential Medicines List (WHO/ EML) lists soluble insulins and intermediate insulins (126). 
However in their latest guidance on the management of patients with diabetes including T1DM, the 
WHO suggests long-acting insulin analogues can be used to control blood glucose levels in patients 
with T1DM who have frequent severe hypoglycaemia with human insulin (146). This will be an issue 
in many African countries given considerable differences in costs and existing concerns with the 
routine availability of NPH insulins (107, 147). 
Insert Table 3
Boxes 1 to 6 contain suggested activities that can be undertaken to improve the care and outcomes of 
patients with T1DM in Africa, Activities for healthcare professional groups and patients/ patient 
organisations are broken down into short and longer term activities.
Alongside these activities, African governments need to see how they can procure insulins and 
monitoring technologies at more affordable prices for patients where there are concerns with high co-
payment levels. The private sector can play its role by lowering prices and/ or enhancing access 

































































programmes in Africa building on existing initiatives (46, 103). In addition in their procurement 
negotiations, African countries need to use their own and surrounding countries’ existing price data in 
theirs and surrounding countries to negotiate improved prices with the potential for developing 
mechanisms to foster competition and secure supplies of insulin with only a limited number of 
companies supplying them with insulin (109).  In time as more biosimilars become available, 
increased competition should lead to lower prices and greater availability across Africa (building on 
Table 3) (107). Improved forecasting and distribution systems should help reduce stock-outs building 
on recent initiatives in South Africa (4).
Insert Boxes 1 to 6
4. Discussion and next steps
There is a growing prevalence of patients with T1DM across Africa. Increased morbidity and mortality 
can be expected in view of the number of patients not diagnosed or misdiagnosed, concerns with the 
routine availability of insulins even those within country’s EML, and high co-payments for insulins in a 
number of African countries. High co-payments for glucose monitoring equipment and testing strips 
across many African countries add to the patient’s and families’ financial burden.  The consequences 
are potentially catastrophic for families. There are also concerns regarding the lack of HCP support 
including education and psychosocial support. Specialists are also needed to help improve the 
management of patients with T1DM across Africa. This includes help with patients coming to terms 
with their disease as well as help with adherence to the medicines prescribed to reduce the 
complications of T1DM including DKA, hypoglycaemia and microvascular complications. 
Encouragingly, we are seeing patient organisations and NGOs including the IDF playing an increasing 
role among African countries to improve the care of patients with T1DM. This is likely to grow. A 
greater focus is also ongoing among countries to improve the management of patients with NCDs. 
Boxes 1 to 6 provide suggestions for governments as well as all key stakeholder groups to improve 
the care of patients with T1DM both in the short and longer term. We will be monitoring this progress 
in the future as countries seek to improve the care of their patients with T1DM. Diagnosis and 
management rates for patients with diabetes including T1DM need to be appreciably improved across 
Africa to achieve the World Health Organisation’s (WHO) 25×25 Global Action Plan (2013) as well as 
Sustainable Development Goal (SDG) 3 goal to reduce premature deaths due to NCDs across 
countries by a third by 2030 (148-152). With respect to increasing the routine availability of insulins 

































































alongside reducing co-payments where concerns, it is better for countries to focus initially on 
increasing the availability of NPH insulins as opposed to more expensive insulin analogues apart from 
insulin resistant patients. This is because a number of published studies from academic and HTA 
units have not demonstrated significant differences between NPH and the more expensive long acting 
insulins in terms of reducing hypoglycaemia episodes or on patient’s quality of life (153-160). 
However, this finding was not universal (161). More recently, long acting insulins have been 
recommended as second line in patients who are allergic to conventional insulins or have failed to 
have their T1DM controlled with conventional insulins (146, 162, 163). First though the availability of 
WHO EML recommended insulins (126) needs to become routine at affordable prices to patients; 
preferably free-of-charge. In addition, it is also important to increase the availability and affordability of 
glucose monitoring equipment and strips to further improve future care.
We are aware of a number of limitations with our study. This includes the fact that we did not 
undertake a systematic review for the reasons already mentioned. We are also aware that there have 
been a paucity of studies assessing the influence and impact of interventions to improve the care of 
patients with T1DM among African countries. However, we have incorporated the views of a wide 
variety of senior level personnel from across Africa with experience of managing, organising, 
researching or educating others about the care of patients with T1DM to help address such concerns. 
Consequently, we believe our findings and suggestions are robust.
 
5. Conclusion
The improved management of patients with T1DM across Africa is starting to be addressed as 
countries develop and refine their action plans to improve the care of patients with NCDs as part of 
SDG goals, with further suggestions contained in Boxes 1 to 6. However, there are still considerable 
concerns and all key stakeholder groups need to work together to appreciably improve the future care 
and self care of patients with T1DM across Africa. 
We will be monitoring developments regarding the future management of T1DM among African 
countries, including the impact of interventions to improve their care. In addition, it is important to 
rapidly publish any findings so that African countries can learn from each other. 


































































Table 1 - Epidemiology of Type 1 diabetes across Africa
Country Epidemiology
General  (45, 62)  Incidence rates of 4.3 per 1000000 among African children 
aged between 0 to 14 years and 10.3 per 1000000 in those 
aged between 0 and 19 years
 Prevalence rates of 10.3 per 1000000 among African children 
aged between 0 to 14 years and 25.8 per 1000000 in those 
aged between 0 and 19 years
 These incidence and prevalence rates are appreciably lower 
than those seen in other regions of the world with incidence 
rates as high as 25.1 per 1000000 among children in Europe 
aged between 0 to 14 years and up to 31.1 per 1000000 in 
those aged between 0 and 19 years
 There is an increase in pregnant adolescents girls presenting 
with T1DM in SSA
Botswana  The IDF currently estimates that the national prevalence rates 
for diabetes among adults is 5.5% (77)
 The number of children and adolescents with T1DM in 
Botswana was recently (2019) estimated at 99 (164)
Cameroon  The number of children and adolescents with T1DM in 
Cameroon was recently (2019) estimated at 743 (164)
Ethiopia  The incidence rate of diabetes among children in Ethiopia in 
2013 aged between 0 and 14 years was 0.3 per 100,000 in 
2013 (26, 165)
 In their study, Balcha et al. (2018) found an appreciably higher 
rate of T1DM in urban areas (incidence rate of 11.9/ 100,000 
for men and 6.1/ 100,000 for women) vs. rural areas (2.2/ 
100,000 for men and 1.0/ 100,000 for women) (73)
 Currently in Ethiopia, it is estimated (2019) that 2127 children 
and adolescents have T1DM (164)
Gabon  Reported incidence rates of 3.4/ 100,000 inhabitants/ year in 
2015 and 2.9 in 2017 (57)
 It is estimated that 89 children (2019) in Gabon currently have 
T1DM (164) 
Ghana  The overall prevalence of diabetes in adults in Ghana was 
3.3% in 2014; principally T2DM (30), with higher rates seen in 
urban towns (30, 68)
 This has risen to 3.6% in 2017 (518,400 cases of diabetes in 
Ghana principally T2DM) (166)
 Currently in Ghana, it is estimated (2019) 1209 children and 
adolescents have T1DM (164)
Kenya  Currently in Kenya, it is estimated (2019) 1694 children and 
adolescents have T1DM (164)
Morocco  The overall prevalence of diabetes in adults in Morocco is 
7.3%, much of which will be patients with T2DM as opposed to 
T1DM (167-169)
Namibia  Adekanmbi et al. (2019) recently estimated the prevalence of 
diabetes in Namibia at 5.1% including patients with T1DM and 
T2DM (170)
 Currently it is estimated (2019) in Namibia that 127 children 
and adolescents have T1DM (164)
Nigeria  Hospital based studies published in 2010 and 2013 showed 
prevalence rates of T1DM up to 3.1/1000 among children aged 
15 years or below (90, 171)

































































 However, there is appreciable variation depending on the 
locality ranging from 0.1/1000 in the South-East of Nigeria , 
0.33/1000 in Sokoto (extreme North-West of Nigeria), 2.3/1000 
in Kano (North-West), and 10.1/1000 in Jos, North-Central (84, 
171-173).
 The IDF currently estimates (2019) that there are 2954 children 
and adolescents in Nigeria with T1DM (164)
Rwanda  The overall prevalence of diabetes in Rwanda is approximately 
3% of the population, mainly T2DM (174)
 Currently (2019) there appear to be over 630 children and 
adolescents in Rwanda with T1DM (164)
Somalia  The IDF currently estimates (2019) that there are 57 children 
and adolescents in Somalia with T1DM (164)
South Africa  In South Africa in 2015, approximately 2.3 million people had 
diabetes principally T2DM (67), with estimates of 1599 children 
and adolescents  with T1DM in 2019 (164)
 However there is a high rate of misdiagnosis in both sectors in 
South Africa as well as high rates of DKA (34)
 Diabetes Type 1A class found to be more prevalent among 
young black South Africans than their white/ Indian peers (175)
There is increase
Sudan  Incidence estimates were 10.3/100,000 in 1995 (176)
 Recently, the IDF currently estimated (2019) there are 208 
children and adolescents in South Sudan with T1DM (164)
Tanzania  Incidence rate among children in Tanzania aged between 0 
and 14 years in 2013 was 0.9 per 100,000 in 2013 (26, 165)
 More recently, Jasem et al. (2019) calculated an annual 
incidence of between 1.8 to 1.9 per 100,000 children aged 
under 15 years, with a peak incidence at 10 to 14 years (165)
 The IDF currently estimates (2019) there are 1984 children and 
adolescents in the Republic of Tanzania with T1DM (164)
Zambia  According to the WHO, the overall prevalence of diabetes in 
Zambia is 4.2% with no breakdown between T1DM and T2DM 
(177)
 The number of children and adolescents with T1DM in Zambia 
is currently estimated at 557  (164)
Zimbabwe  Among a total of 29,514 study participants, the overall pooled 
prevalence of diabetes in Zimbabwe including patients with 
T1DM before 1980 was 0.44% (95% CI 0.0-1.9%), and after 
1980 the pooled prevalence was 5.7% (95% CI 3.3-8.6%) 
(178)
 The IDF currently estimates (2019) there are 464 children and 
adolescents in Zimbabwe with T1DM (164)
NB: DKA= diabetic ketoacidosis; IDF: International Diabetes Federation; T1DM: Type 1 Diabetes mellitus; T2DM: 
Type 2 Diabetes mellitus; WHO: World Health Organization

































































Table 2 – Economics of diabetes across Africa especially T1DM, insulin availability and glucose strips
Country Summary details
Sub-Saharan Africa  Ogle et al. (2016) ascertained that the median cost of blood 
glucose strips among seven African nations was US$0.50, 
and the minimal reasonable yearly costs to families with a 
child or adolescent with diabetes ranged from 74% to 377% 
of per-capita gross income (1, 129) 
 The regular availability of monitors and test strips is rare for 
most patients in African countries with the cost of monitoring 
beyond the financial means of most families, and many 
clinics currently cannot routinely measure glucose levels (17, 
129, 179)
 Only a limited number of governments among those 
documented by Ogle et al. (2016) fully provided insulin (129) 
 The mean availability of insulins in the public sector ranged 
from 55% to 80% among 13 LMICs including four African 
countries (107). Median government procurement prices for 
human insulins was US$5 among the 13 countries (107)
 Wide variations have been seen in the prices of a 10-ml, 100-
IU/ml vial equivalent of insulin ranging from US$1.0 to US$ 
11.5 (median US$ 4.7) among countries in the WHO 
Regional Office for Africa (109)
East Africa Many patients on cost and other grounds still reuse syringes, 
which is discouraged as this can increase lipohypertropy (128) 
Burkina Faso Estimated published minimal annual direct costs of treating 
T1DM patients and supplies is US$1185 (129), equating to 177% 
per capita income 
Egypt  In their study, Zhang et al. (2010) documented Egypt’s 
healthcare expenditure for patients with diabetes including 
both T1DM and T2DM reached US$ 116 per person - 16% of 
total healthcare expenditure (23, 180)
 Expenditures are currently likely to be considerably more 
than this, with greater expenditure per person among 
patients with T1DM versus T2DM
Gabon  Damiens et al. in their study (2019) found that in 76% of 
patients with T1DM the cost of the medicines was an 
obstacle to the adherence to the medicines prescribed (57), 
with 69% saying they do not have a supply of blood sugar 
test strips to adapt insulin doses
 In view of the financial effects of the disease, if patients are 
alive after 4 years post diagnosis they typically have poor 
metabolic balances and recurrent DKA resulting in premature 
death (57)
Ghana  The total cost of diabetes for 40 households in Ghana 
including patients with both T1DM and T2DM was 
approximately 15,000 Cedi/month in 2015 of which 66.5% 
was direct costs (30)
 Overall, 52.9% of the households surveyed in Ghana 
experienced catastrophic health expenditure (30)
Kenya  Ngwiri et al. in their study (2015)  found that 69% of children 
there were concerns with the unavailability of mixed 
formulation insulins (65)
 In their study, Pastakia et al. (2018) found that 85% of 
patients with diabetes including both T1DM and T2DM being 
treated at Webuye District Hospital (rural diabetes clinic) 
received regular HbA1c testing (181). This is welcomed with 
the average cost of HbA1c measurement at US10 – 25 with 

































































50% of residents typically living on less than 1US$/ day (6, 
17, 182)
 The management of patients with diabetes in Kenya 
including T1DM patients is a key Government objective to 
reduce morbidity and mortality rates (54)
 In their recent study, Shannon et al. (2019) found that despite 
a ceiling price ceiling of US$5 per vial of insulin, many 
patients could not afford the additive expense of care 
including monitoring, other medicines and travel to the 
clinics. Encouragingly though, there was a greater number of 
stock-outs among facilities not taking part in the access 
scheme (46)
Mozambique  The government currently buys insulin at approximately 
US$4.30/ vial. Since the average person requires 13 vials a 
year, the government must prioritise whether it provides 
insulin for one person or essential medicines for nearly 40 
others (47)
 In addition in Mozambique, previously only a limited number 
of facilities have the necessary equipment to undertake blood 
glucose analysis (47); however, this is now being addressed 
with the help of the IDF
Namibia  There is universal access to cost-free diabetic care in 
Namibia’s public sector, which can be accessed from primary 
health care to tertiary institutions (5)
 A wide range of insulins including soluble and long acting 
insulins are available to the public via PHCs financed by the 
government of the Republic of Namibia
 A wide range of insulin preparations can also be accessed in 
the private sector as well as through a cost sharing system, 
Average co-payments range from US$3.4 to US$5.1 per vial. 
Without medical aid insurance, the cost of insulin 
preparations would range from US$11.3 to US$17.1 per vial 
 The challenges of managing patients with T1DM include: 
long distances between homes and health care facilities for 
people in the rural areas where the cost of transport and lost 
wages needs to be factored in as well as a a lack of 
appropriate storage systems in rural settings
Nigeria  Medication costs accounted for 72.3% of the total direct cost 
of patients with diabetes followed by the cost of laboratory 
investigations (17.6%), with costs typically out-of-pocket 
(183). Other studies have suggested that the costs of 
medicines can account for up to 90% of total costs (27)
 Ogbera et al. (2012) estimated the monthly mean costs of 
insulin was 5212.8 Nigerian Naira (US$33.1) equating to 
29% of the minimum wage on insulin alone for patients with 
T1DM (184)
 In their study, Onyiruka et al. (2012) estimated the mean 
monthly direct cost of routine diabetes care was 10, 950 
Nigerian Naira (US$73) with the insulin responsible for 51.1% 
of this cost (185)
Rwanda  Rwanda’s community-based health insurance system 
covered approximately 80% of the population in 2015–2016 
with growth ongoing as Rwanda strives towards universal 
health coverage (121, 186). The healthcare system also 
covers country’s poorest citizens aiming to enhance access 
to healthcare for all including medicines 
 The Rwanda Diabetic Association is active in many areas 
across the country to improve the care of patients with 
diabetes including T1DM. Activities include running diabetes 

































































awareness programmes, providing relevant information on 
diabetes management including medical treatment, training 
HCPs, as well as creating a network between key diabetes 
care stakeholders and a registry of diabetic patients in 
Rwanda. Activities also include providing information to 
children and young adults on insulin (187)
 Other initiatives to improve the care of patients with T1DM 
in Rwanda include the Team Type 1 Foundation and Abbott  
to donate glucose meters as well as nearly 12 million test 
strips (53)
South Africa  The cost of hospitalisation due to diabetes in South Africa 
ranges from I$ 80 to I$ 461 (27), with the treatment of DKA 
put a further strain on the system due to late presentations 
(34)
 There are concerns glucose testing strips are not available 
to every patient and children are being treated with 
premixed insulin without access to rapid-acting insulin in 
public health facilities (93)
Sudan  Encouragingly, the Audit Report of Global Fund Grants for 
the Republic of Sudan (2019) stated that the national 
medicines supply fund (NMSF), which is the public supply 
agency in Sudan, has robust processes and controls (188)
 This is illustrated by the NMSF had never experienced 
stock-outs of insulin from 2013 to 2018. In addition, the 
NMSF has continued to supply insulin at fixed prices to the 
country because it has continued to use a fixed exchange 
rate of SDG18 for US$I.00 for procurement despite the high 
inflation rate in Sudan, e.g. 63.3%, 2018. Consequently, 
public healthcare facilities in Sudan have managed to have 
a continuous supply of insulin preparations at prices lower 
than private sector (189):
o Insulin (Mixtard®): Public retail price US$0.82 
Private retail price US$4.76
o Insulin (Actrapid®) Public retail price US$0.82, 
Private retail price US$4.76
o Insulin Glargine: Public retail price US$4.52, Private 
retail price US$8.40.
 However, the cost of T1DM is still a burden to families as a 
significant percent of household out-of-pocket expenses are 
used on medicines and medical consumables. 
 A study published in 2005 reported that the direct cost of 
diabetes care required 65% of the health expenditure of the 
whole family with the costs of insulin constituting 
approximately one-third of the total diabetes care 
expenditure (190)
 A more recent study showed that a four-fold increase in the 
cost of managing diabetes in Sudan occurred between 2005 
and 2013 (191), with costs expected to rise further 
Zambia  In Zambia, there are initiatives in place for patients to receive 
free or subsidized insulins through the national health 
insurance scheme operationalised in 2020 (47)
 However, even at an average price of US$2,00/ vial for 
insulin this is still a financial burden in countries where many 
patients live on less than US$1.00/ day (47)
 Overall insulin (soluble) was available in 38% of facilities 
recently surveyed by Mutale et al. (2018) and 18% in rural 
facilities (33)

































































 Kalungia et al. (2017) also confirmed that stock-outs were 
high for short acting (83%) and long acting (69%) 
preparations among the surveyed healthcare facilities (192)
 Kaiser et al. (2019) also found variable availability of insulins 
(short acting, intermediate acting and 30/70) ranging from a 
low of 4.6% among 99 surveyed pharmacists in three 
adjacent provinces in Zambia up to a 46.4% (193). Median 
prices of insulins also varied among the different pharmacies, 
e.g. between US$11.33 to US$24.79 for intermediate insulin 
and  US$16.80 - $US28.82 for insulin 30/70 (193)
 The routine availability of glucose strips at public healthcare 
facilities is still irregular with issues of affordability
 Socioeconomic circumstances continue to hamper the use of 
advanced technologies to manage T1DM in Zambia. Major 
barriers to address include not only poverty and poor access 
to diabetes care, but also lack of knowledge among 
caregivers of T1DM patients which often leads to increased 
risk of misdiagnosis and late detection of T1DM (99).
NB: HCP: Healthcare Professional; T1DM = Type 1 diabetes; T2DM = Type 2 diabetes; PHCs = Primary 
healthcare centres
Table 3 – Facilities and treatments available in the public healthcare system among African countries 
to manage T1DM and its complications
Country Treatments and Facilities
Botswana  Random blood glucose within public healthcare facilities is part and 
parcel of the initial evaluation when patients first present with suspected 
diabetes in Botswana
 Insulins routinely available among public healthcare facilities in 
Botswana include: 
 Short-acting regular human insulins 
o Actrapid
o Rapid-acting analogue insulins 
o Aspart (NovoRapid) 
o Glulisine [Apidra] 
 Intermediate-acting (basal) human insulins 
o NPH - neutral protamine Hagedorn
 Long-acting (basal) analogue insulins 
o Glargine [Lantus]
 Pre-mixed human (biphasic) insulins 
o 30% Regular + 70% NPH [Actraphane]
 Pre-mixed analogue insulins 
o Rapid-acting plus basal (NPH)
o Biphasic aspart [NovoMix-] 
o Biphasic lispro [Humalog Mix25] 
NB: Most of these drugs are available in specialized diabetes clinics. In non-
specialised clinics, only a few insulins are available on specialist prescription 
forms (special order- NovoMix, NovoRapid).
 Treatments available to help manage the complications of T1DM within 
the public healthcare system include:
o Medicines, e.g. blood pressure medicines – routinely available 
free of charge within public healthcare facilities 
o Procedures: retinal photocoagulation, renal replacement therapy 
by dialysis (both haemodialysis and peritoneal dialysis are 
available in tertiary healthcare facilities with the costs covered by 
the Government of Botswana), and renal replacement therapy 
by transplantation (currently performed outside of Botswana with 
the costs covered by government); coronary artery disease 
treatment is also available for diabetes patients where pertinent

































































o Basic technologies: Blood glucose measurement, Urine strips for 
glucose and ketone measurements, HbA1c 
Cameroon  Patients are routinely seen by nurses and general practitioners in the 
Cameroon, with specialist care only available at regional or reference 
hospitals
 All care is currently out of pocket. Micro insurance schemes do not cover 
medical costs for diabetes or related conditions.
 Random blood sugar, fasting blood sugar, and urinalysis are routine 
tests to assess the care of patients with T1DM. HbA1c is not available.
 Available options for insulin include INSULET RAPID (DCI: INSULINE 
GLARGINE 1000 UI/mL) ; INSULET MIX (DCI: INSULINE GLARGINE 
1000 UI/mL); and INSULET NPH (DCI : INSULINE GLARGINE 100 
UI/mL)
 Chronic disease support groups known as Non-Communicable Disease 
clinics are common and provide monthly services to patients mostly for 
checkups
Ghana  Insulins currently available in the Ghana EML for prescribing in PHCs 
include Insulin Aspart, Insulin Detemir, Insulin Glargine, Insulin Lispro, 
Insulin Soluble, Insulin Isophane (NPH) and Premixed (mixture of soluble 
insulin and intermediate NPH insulin in a 30:70 ratio) 
 The only insulins available under the National Health Insurance Scheme 
(NHIS) include insulin soluble, NPH and Premixed (30/70) while the rest 
are purchased out of pocket when prescribed (194)
 Whilst some basic laboratory tests such as fasting blood glucose are 
provided under the NHIS, other relevant routine tests such as HbA1c 
and other supplies such as glucometer test strips and insulin syringes 
and needles currently have to be paid for out-of-pocket
 Patients in PHCs are typically reviewed every 2-3 months and given 
refills of their insulin based on current availability at PHCs. However, not 
all health centres have dieticians and patients have to typically rely on 
their physician or nurse for food/nutrition advice
 Complicated cases of T1DM requiring advanced specialist care including 
dialysis, renal replacement therapy are referred to one of the few 
available tertiary hospitals. Advanced care is not covered by the NHIS 




Insulins listed in the EML of the Kingdom include:
1. Soluble insulin 100units/ml injection
2. Isophane 100units/ml injection
3. Zinc insulin 100units/ml injection
4. Insulin+Isophane (30/70) 100units/ ml injection
Namibia  A wide range of insulins including soluble and long acting insulins are 
available to the public via PHCs financed by the government of the 
Republic of Namibia.
Nigeria  Short acting or meal time insulins, premixed insulin and insulin glargine 
are in the Nigerian EML. However, there are problems with availability 
and affordability of insulin glargine
 The Diabetic Association of Nigeria has been involved with the 
development of practice guidelines in Nigeria to improve the care of 
patients with diabetes. The association has also had agreements with 
pharmaceutical companies to reduce the cost of their medicines to 
increase access and usage
 There is typically routine monitoring of blood glucose using glucometer 
and laboratory testing in patients treated in secondary and tertiary 
hospitals. Routine monitoring of HbA1c is typically too expensive for 
most patients due to high co-payment levels in Nigeria
 There are typically yearly referrals to eye clinics for assessment and 
treatment as well as routine treatment for systemic hypertension and 
dyslipidaemia when this occurs. Dialysis facilities are available but can 
be problematic in view of the costs involved

































































South Africa  Screening of diabetes occurs at all levels of care depending on the 
patients’ clinical conditions and their complaints 
 Random and fasting blood glucose within any healthcare facility is part 
and parcel of the initial evaluation 
 Insulins routinely available with public healthcare facilities include:
o Insulin, short acting Regular human insulin
o Insulin, intermediate acting
o Insulin, biphasic mixtures of regular human insulin and 
intermediate acting insulin in different proportions, e.g. 30/70 
(30% regular insulin and 70% intermediate acting insulin).
 Treatment is typically initiated by medical doctors at any level of care 
within the public system depending on the availability of the physicians in 
PHC facilities on the day of consultation, with maintenance medicines 
sent to the PHC facilities monthly from the supporting district and 
regional hospitals
 Stable patients are typically reviewed every six months 
 Basic technologies include blood glucose measurement, urine strips for 
glucose and ketone measurements, HbA1c, retinal examinations, renal 
function tests, neurological examinations, continuous blood sugar 
monitoring
 Non-pharmacological management discussed include: diet, physical 
activity, lifestyle advice, behavioural therapy
 Dialysis is available at the provincial and tertiary hospitals 
 However, there have been concerns with suboptimal control of 
hyperglycaemia in Africans despite being on treatment leading to calls 
for greater monitoring to reduce complications (195)
 This has resulted in projects including TIP – a collaboration between the 
University of Pretoria, the Department of Health nationally and locally, 
and the City of Tshwane - Tshwane Insulin Project (TIP) initiated in 2018 
and funded for over five years by Eli Lilly and Company. The TIP 
recognises concerns with initiating and optimising the use of insulin in 
patients with diabetes, with improving the management in primary care a 
key goal (196, 197) – building on concerns with the lack of HCPs trained 
in insulin use as well as patient-related factors including psychological 
fears with diabetes and insulin in South Africa
 Under the TIP, there will be a major role for HCPs in primary care 
including primary care nurses and clinic physicians to help diagnose, 
initiate and monitor the use of insulins as well as test the feasibility of 
telemedicine and phone apps to improve the care of patients especially 
in more rural areas (196)
Sudan Insulin preparations listed on the Sudan NEML are (198):
 Short acting (soluble) Insulin
 Glargine
 Insulin Lispro 
 Insulin mixed
 Intermediate-acting insulin
Based on the actual need as specified by the practitioners, NMSF covers 




Zambia  Insulin preparations listed on the Zambia EML are:
o Short acting (soluble) Insulin
o Isophane Insulin, Biphasic Insulin
o Actraphane or mixtard (30/70) 
o Long acting insulins
In Zambia, healthcare interventions available to prevent and manage 
complications include: 

































































o Available routine monitoring of blood levels including BP 
measurement/treatment across all levels of public healthcare
o At level 2 and 3 (district and tertiary hospitals), monitoring of patients 
regarding the development of retinopathy, neuropathy, etc., typically 
takes place
o Dialysis for patients with nephropathy is mostly available at tertiary 
level hospitals
o Referral and treatment of diabetes ketoacidosis takes place at level 
2 and 3 hospitals
 Diabetes clinics manned by specialist physician established at level 2 
and 3 hospitals
Zimbabwe  Listed in the Zimbabwe EML include:
o Bolus insulins, e.g. rapid and short acting insulins including 
ASPART and ACTRAPID
o Intermediate and long acting insulin analogues including 
biphasic insulins (30/70), PROTAPHANE as well as insulin 
glargine and degludec
 T1DM is typically treated starting in district hospitals. Routine laboratory 
testing facilities are available but there are concerns with the lack of 
consumables. In addition, the cost of tests is a deterrent for most 
diabetic patients in public institutions compromising their chronic care
 Complications associated with T1DM are assessed as part of routine 
care by physicians at eye and diabetic clinics including those in tertiary 
level facilities
 Dialysis is available at some provincial hospitals as well as in all 5 
central hospitals in the country
NB: EML = Essential Medicines List; T1DM = Type 1 diabetes; PHCs = Primary healthcare centres
Box 1 – National/ regional governments and authorities
Leadership and governance
 Commit at the highest level to make quality T1DM healthcare services and medication based 
on current guidelines within countries available for all T1DM patients. In the long term, this 
should be free at the point of delivery irrespective of the ability of patients or their families 
 Instigate initiatives to highlight to key government and other officials that T1DM is a public 
health concern across Africa. As part of these initiatives, include primary healthcare and 
disease prevention as part of a national health strategy to reduce morbidity and mortality due to 
NCDs
 Institutionalise routine screening for potential patients with T1DM in all healthcare facilities 
including both symptomatic and asymptomatic patients, and make screening free of charge. A 
key area will be primary healthcare centres within public healthcare systems as opposed to 
hospitals and specialist clinics
 Provide incentives for increasing the number of endocrinologists within a country where 
pertinent. In the short term, this could include using International aid to boost the number of 
endocrinologists within a country
 Introduce/ expand effective chronic disease management systems of care for patients with 
T1DM to improve the efficiency of care delivery
 Strengthen policy and systems towards T1DM management including encouraging adherence 
to WHO guidance as well as regular updates on country guidelines and NCD policies that 
incorporate T1DM. In addition, encourage operational research to monitor improvements in 
care delivery. As part of this, seek to provide direct economic, medical and social support for 
families with a child with T1DM
 Restructure where pertinent inventory management and procurement systems for insulin and 
its accessory devices nationally and among PHCs to ensure routine availability and 
accessibility to all types of insulin necessary for the effective management of patients with 
T1DM


































































 Increase recruitment/ retention of general practitioners, family physicians with an interest in 
diabetes, dieticians, specialist pharmacists, and clinical psychologist with a special focus on 
PHCs for comprehensive clinical management in line with a growing focus on PHCs to 
diagnose and manage patients with T1DM in Africa. This alongside greater recruitment and 
retention of endocrinologists in Africa. As a result, improve and attain a good distribution of a 
relevant healthcare workforce across the spectrum 
 Task shifting to enable pharmacists, nurses and community healthcare workers help run 
diabetes clinics and educational initiatives in both urban and rural settings 
 Introduce a syllabus for HCPs on NCDs including T1DM so that all staff including clinical and 
non clinical staff can create a common language and framework for managing patients with 
T1DM
 Following this, regular continuous training and performance development for of all HCPs to 
improve their diagnosis and care of patients with TIDM including prevention and treatment of 
potential complications. This includes information of the mechanism of action of medicines and 
potential adverse events – and as part of this look to make available charts on how to manage 
T1DM including self-monitoring and potential complications
Medical products and technologies
 Improve the availability and supply of products and technologies used for T1DM management 
including routine/ consistent availability of insulins on the WHO EML as well as making fasting 
blood sugar levels and HbA1c testing more affordable for patients. This can be through 
collaborations with NGOs especially around the free provision of glucometers and test strips
 In the long term seek to include routine availability of long acting analogues with the increasing 
availability of biosimilars 
 Explore solar- dependent refrigeration for insulin preparations at the household level especially 
in rural settings
 Consider non-invasive methods of glucose monitoring to improve compliance to self-care 
modalities
 Utilise cost-effective interventions
 Commit in the longer term for governments and health authorities to use HTA as part of 
decision-making processes to guide investment and funding decisions based on the efficacy, 
effectiveness, safety and cost-effectiveness of different technologies
Financing
 Improve healthcare financing towards T1DM management to reduce current morbidity and 
mortality rates. This can include expansion of health insurance towards universal access in a 
number of African countries
 This includes reducing or negating out-of-pocket payments and co-payment for insulin as well 
as for monitoring including glucose strips
 Improve medicine and product quality, access and pricing mechanisms to control for 
substandard products as well as improved prices given the price variations in insulins and other 
medicines to manage patients with T1DM across Africa and within countries 
 Incentivise pharmacists as well other HCPs to establish medicines management centres in 
rural settings
 Research and Innovation
 Invest in epidemiological research where this is currently lacking including potentially the 
establishment of a national surveillance system/ databases for patients with T1DM to improve 
monitoring and evaluation of care delivery. This can include the introduction of IT systems/ 
electronic medical records to enable monitoring of care at the patient level
 Invest in HTA research where this is lacking to enable greater critique of evidence based 
potential alternatives within finite resources to improve efficient use of resources 
 Invest in research surrounding possible innovative solutions including cost-effective solutions
 Encourage greater collaboration and linkage between research institutions, academia and 
policy makers
NB: EML = Essential Medicines List; HCPs = Healthcare professionals; HTA = Health Technology Assessment; 
T1DM = Type 1 diabetes; PHCs = Primary healthcare centres; NCDs = Non-communicable diseases; WHO = 
World Health Organisation

































































Box 2 – Physicians (hospital and ambulatory care)
Short term
 Including greater opportunities for training and re-training of ambulatory care physicians in the 
management of patients with T1DM starting in pharmacy and medical schools and progressing 
to in-service training. This can also include greater knowledge surrounding key issues such as 
adherence to the medicines prescribed for both T1DM and its complications as well as the 
need for greater psychological support to improve patient care
 Work with key agencies to develop local evidence based guidelines for the management of 
patients with T1DM. These can subsequently be used as a basis for future quality improvement 
programmes
 Encourage more specialist doctors in fields such as endocrinology to contribute to better of 
patients with T1DM across Africa
 Work with others to seek to improve the availability of medicines for all T1DM patients
 Work with others to address ongoing bottlenecks in the pharmaceutical supply chain of T1DM 
medicines and products as well as working with others to help ensure quality and affordable 
medicines and technologies
Longer term
 Seek to attain a good distribution of physicians across the spectrum of health service provision, 
and geographical areas (rural and urban) settings
 Regular updating of guidelines when any changes in available medicines and technologies
NB: T1DM – Type 1 diabetes
Box 3 – Pharmacists (hospital and ambulatory care)
Short term
 Continuous training and re-training of pharmacists regarding the management and education of 
patients with T1DM starting in pharmacy school
 Improve the participation and role of community pharmacists in providing care to patients with 
T1DM including counselling especially dealing with key issues such as re-fill prescriptions, 
insulins and needles as well as glucose monitoring. Include patient education to empower them 
to address key issues such as adherence, diet and lifestyles as well as concerns with the 
impact of T1DM on their quality of life
 Enhance the role of pharmacists in pharmacovigilance, medication error reporting and quality 
assurance of medicines and products used in T1DM. This can include the employment of 
Doctor of Pharmacy graduates (where these exist) in the public healthcare sector to improve 
patient-centred care
 Integrate and accredit community pharmacy services within national health insurance schemes. 
Services can be enhanced by introducing additional pharmacist training on the care of patients 
with diabetes. Look to include mandatory continuous performance development programmes  
 Establishment and strengthening of medicines information services to all healthcare 
professionals as well as patients
 Encourage proactive data collection, analysis and feedback to both patients and healthcare 
providers at the facility level in terms of agreed diabetes management monitoring indicators
Longer term
 Conduct research and development of novel treatment modalities, medicines and products, 
including pharmacogenetics of T1DM in the population
 Provide incentives and opportunities for operational research on NCDs such as T1DM
 Potentially seek to establish pharmacist-led diabetic services at all levels of healthcare to 
address concerns with available facilities and personnel
NB: T1DM – Type 1 diabetes

































































Box 4 – Healthcare professionals in ambulatory and hospital care including nurse practitioners
Short term
 Enhance competences and skills of the healthcare workforce to better diagnose and manage 
patients with T1DM through improved training including in-service training. Look to include the 
development and introduction of dedicated diabetic nurse educators
 Seek to train ambulatory and acute hospital care staff regarding any relevant advances and 
technologies used in the care of patients with T1DM 
 Routinely provide relevant equipment for their roles 
Longer term
 Undertake quality improvement research to address gaps in strategies and technical aspects to 
improve future service delivery
NB: T1DM – Type 1 diabetes
Box 5. Health technology (other than pharmaceutical therapy)
Short term
 Continuous training and re-training of clinical technologists regarding the management of 
patients with diabetes
 Enhance the role of clinical technologists in surveillance, quality assurance of results and 
products used in T1DM. This can include the employment of clinical technology graduates 
(where these exist) in the public healthcare sector to improve patient-centred care
 Integrate and accredit community laboratory services within national health insurance scheme, 
enhanced by introduced of additional training on the care of patients with diabetes. This can 
ultimately include mandatory continuous performance development programmes  
Longer term
 Involvement of biomedical engineers for development of newer diagnostic techniques 
 Conduct research and development of novel diagnostic modalities that are affordable and can 
improve the management of patients with T1DM efficiently (such as continuous glucose 
monitoring system)
 Provide incentives and opportunities for operational research on NCDs such as T1DM
 Involvement of experts in Health Technology Assessment for measuring the impact of different 
health technologies on the future management of patients with TIDM
NB: NCDs = Non-communicable diseases; T1DM – Type 1 diabetes
Box 6 – Suggested activities among patients/ support services
Short term
 Encourage the development and expansion of patient support networks to enhance the 
identification and subsequent management of patients with T1DM including the importance of 
diet and physical activities as well as the need for psychological management for patients with 
T1DM. For instance, in Zambia, the Diabetes Association of Zambia has been key in 
encouraging and engaging key stakeholder groups on diabetes matters, with the Diabetes 
Association in Nigeria playing a key role in guideline development and securing lower prices for 
medicines
 Undertake health education to communities to increase awareness, access to care and social 
support for patients with T1DM. This can include establishment of youth groups for children and 
adolescents in every community. Such groups can promote self care and reduce stigmatization 
associated with T1DM through group sharing of experiences
Longer term
 Instigate comprehensive adolescent health initiatives as part of patient education programmes 
that help to reduce the complications of T1DM including DKA, neuropathy, nephropathy and 
CV diseases
 Developing pertinent initiatives among T1DM patients and their families, particularly among 
adolescents, to ensure acceptance of diabetes and ant diabetes care plan as part of their lives 
- viewing diabetes as manageable and as their responsibility. As part of this, work with patients 
and patient organisations to gain valuable information on diabetes and diabetes management 
to improve future care (199) 

































































 Encourage greater patient engagement and involvement in the health technology assessment 
process
NB: DKA= diabetic ketoacidosis; T1DM – Type 1 diabetes
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